Gilder Gagnon Howe & CO LLC Pro Qr Therapeutics N.V. Transaction History

Gilder Gagnon Howe & CO LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.8 - $3.7 $20 - $96	-26 Reduced 0.03%	96,993 $358,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $597 - $719	-808 Reduced 0.83%	97,019 $72,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.0 $13 - $24	-24 Reduced 0.02%	97,827 $76,000
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $1.15 Million - $10.7 Million	-1,281,272 Reduced 92.9%	97,851 $89,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $1.49 Million - $1.91 Million	226,211 Added 19.62%	1,379,123 $11 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $3.27 Million - $5.37 Million	634,179 Added 122.26%	1,152,912 $9.65 Million
Q2 2021 Aug 16, 2021	BUY	$5.75 - $7.59 $2.98 Million - $3.94 Million	518,733 New	518,733 $3.5 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $151M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.